Samina Afreen is an Endocrinology/Metabolic physician affiliated with University of Virginia. OpenAlex indexes 28 publications with 227 citations (h-index 6); ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
415 Ray C Hunt Dr Ste 2100
Charlottesville, VA 229032980
Telephone
434-243-4620Provider last certified this registry record 8 Aug 2023.
Clinical trials
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Ascendis Pharma Endocrinology IncProgram year20254 payments
- Ascensia Diabetes Care Us Inc.Program year20241 payment
- Novo Nordisk IncProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
40.1%Insulin Analog12.3%Humalog Kwikpen U-10033%Lantus Solostar31%Lantus26%Humalog10%Part D<11 patientsGLP-1 receptor agonist9.7%Ozempic51%Trulicity34%Mounjaro15%Part D<11 patients+ 5 more classes in this area
Hormonal (systemic)
39.1%l-Thyroxine26.5%Levothyroxine Sodium79%Synthroid21%Part D≥73 patientsParathyroid Hormone Analog5%Teriparatide77%Forteo24%Part D<11 patients+ 3 more classes in this area
Cardiovascular
13.5%Statin8%Atorvastatin Calcium67%Rosuvastatin Calcium17%Simvastatin16%Part D<11 patientsThiazide diuretic1.8%Hydrochlorothiazide100%Part D<11 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Large language models provide unsafe answers to patient-posed medical questions
npj Digital Medicine
2026 - A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes
New England Journal of Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Charles Landen, MD
University of Virginia
Stephen Caldwell
University of Virginia
James Platts-Mills, MD
University of Virginia
Eric Houpt
University of Virginia
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”